Premenopausal serum sex hormone levels in relation to breast cancer risk, overall and by hormone receptor status - Results from the EPIC cohort

Rudolf Kaaks, Kaja Tikk, Disorn Sookthai, Helena Schock, Theron Johnson, Anne Tjønneland, Anja Olsen, Kim Overvad, Françoise Clavel-Chapelon, Laure Dossus, Laura Baglietto, Sabina Rinaldi, Veronique Chajes, Isabelle Romieu, Heiner Boeing, Madlen Schütze, Antonia Trichopoulou, Pagona Lagiou, Dimitrios Trichopoulos, Domenico PalliSabina Sieri, Rosario Tumino, Fulvio Ricceri, Amalia Mattiello, Genevieve Buckland, Jose Ramón Quirós, María José Sánchez, Pilar Amiano, Maria Dolores Chirlaque, Aurelio Barricarte, H. Bas Bueno-De-Mesquita, Carla H. Van Gils, Petra H. Peeters, Anne Andersson, Malin Sund, Elisabete Weiderpass, Kay Tee Khaw, Nick Wareham, Timothy J. Key, Ruth C. Travis, Melissa A. Merritt, Marc J. Gunter, Elio Riboli, Annekatrin Lukanova

Research output: Contribution to journalArticle

Abstract

Results from prospective studies on premenopausal serum hormone levels in relation to breast cancer risk have been inconclusive, especially with regard to tumor subtypes. Using a case-control study nested within the prospective European Prospective Investigation into Cancer and Nutrition (EPIC) cohort (801 breast cancer cases and 1,132 matched control subjects), we analyzed the relationships of prediagnostic serum estradiol, free estradiol, progesterone, testosterone, free testosterone and sex hormone-binding globulin (SHBG) levels with the risk of breast cancer by estrogen and progesterone receptor-positive and -negative breast tumors and by age at diagnoses. Higher prediagnostic serum levels of testosterone and free testosterone were associated with an increased overall risk of breast cancer [ORQ4-Q1 = 1.56 (95% CI 1.15-2.13), ptrend = 0.02 for testosterone and ORQ4-Q1 = 1.33 (95% CI 0.99-1.79), ptrend = 0.04 for free testosterone], but no significant risk association was observed for estradiol, free estradiol, progesterone and SHBG. Tests for heterogeneity between receptor-positive and -negative tumors were not significant. When analysis were stratified by age at tumor diagnosis, the odds ratios observed for estradiol were stronger and borderline significant for breast cancer diagnosed at age less than 50 [ORQ4-Q1 = 1.32 (95% CI 0.87-2.01), ptrend = 0.05] compared to breast cancer diagnosed at age 50 or above [ORQ4-Q1 = 0.94 (95% CI 0.60-1.47), ptrend = 0.34, phet = 0.04]. In conclusion, our data indicate that higher premenopausal circulating testosterone levels are associated with an increased risk of developing breast cancer, but do not show a significant association of estradiol or progesterone with breast cancer risk, overall, by menstrual cycle phase or by tumor receptor status, although a possible risk increase with higher estradiol levels for tumors diagnosed before age 50 was seen. What's new? Sex hormones have often been connected with the development of breast cancer, and estrogens have clear pro-proliferative effects on breast cancer cells. In this large prospective study, the authors underscore a direct association of premenopausal levels of testosterone with subsequent breast cancer risk. By contrast, no direct relationship between premenopausal estrogen and progesterone levels with increased breast cancer risk was observed although a weak association between higher estradiol levels and increased risk for tumors diagnosed before age 50 was noted. The authors point to the possibility that a conversion from androgen to estrogen might take place in the breast that may mechanistically explain the increased risk in breast cancer development when androgens are high.

Original languageEnglish
Pages (from-to)1947-1957
Number of pages11
JournalInternational Journal of Cancer
Volume134
Issue number8
DOIs
Publication statusPublished - Apr 15 2014

Fingerprint

Gonadal Steroid Hormones
Hormones
Breast Neoplasms
Serum
Testosterone
Estradiol
Neoplasms
Progesterone
Sex Hormone-Binding Globulin
Estrogens
Androgens
Prospective Studies
Progesterone Receptors
Menstrual Cycle
Estrogen Receptors
Case-Control Studies
Breast

Keywords

  • breast cancer
  • EPIC
  • estrogen receptor
  • prospective cohort
  • sex hormones

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Premenopausal serum sex hormone levels in relation to breast cancer risk, overall and by hormone receptor status - Results from the EPIC cohort. / Kaaks, Rudolf; Tikk, Kaja; Sookthai, Disorn; Schock, Helena; Johnson, Theron; Tjønneland, Anne; Olsen, Anja; Overvad, Kim; Clavel-Chapelon, Françoise; Dossus, Laure; Baglietto, Laura; Rinaldi, Sabina; Chajes, Veronique; Romieu, Isabelle; Boeing, Heiner; Schütze, Madlen; Trichopoulou, Antonia; Lagiou, Pagona; Trichopoulos, Dimitrios; Palli, Domenico; Sieri, Sabina; Tumino, Rosario; Ricceri, Fulvio; Mattiello, Amalia; Buckland, Genevieve; Ramón Quirós, Jose; Sánchez, María José; Amiano, Pilar; Chirlaque, Maria Dolores; Barricarte, Aurelio; Bas Bueno-De-Mesquita, H.; Van Gils, Carla H.; Peeters, Petra H.; Andersson, Anne; Sund, Malin; Weiderpass, Elisabete; Khaw, Kay Tee; Wareham, Nick; Key, Timothy J.; Travis, Ruth C.; Merritt, Melissa A.; Gunter, Marc J.; Riboli, Elio; Lukanova, Annekatrin.

In: International Journal of Cancer, Vol. 134, No. 8, 15.04.2014, p. 1947-1957.

Research output: Contribution to journalArticle

Kaaks, R, Tikk, K, Sookthai, D, Schock, H, Johnson, T, Tjønneland, A, Olsen, A, Overvad, K, Clavel-Chapelon, F, Dossus, L, Baglietto, L, Rinaldi, S, Chajes, V, Romieu, I, Boeing, H, Schütze, M, Trichopoulou, A, Lagiou, P, Trichopoulos, D, Palli, D, Sieri, S, Tumino, R, Ricceri, F, Mattiello, A, Buckland, G, Ramón Quirós, J, Sánchez, MJ, Amiano, P, Chirlaque, MD, Barricarte, A, Bas Bueno-De-Mesquita, H, Van Gils, CH, Peeters, PH, Andersson, A, Sund, M, Weiderpass, E, Khaw, KT, Wareham, N, Key, TJ, Travis, RC, Merritt, MA, Gunter, MJ, Riboli, E & Lukanova, A 2014, 'Premenopausal serum sex hormone levels in relation to breast cancer risk, overall and by hormone receptor status - Results from the EPIC cohort', International Journal of Cancer, vol. 134, no. 8, pp. 1947-1957. https://doi.org/10.1002/ijc.28528
Kaaks, Rudolf ; Tikk, Kaja ; Sookthai, Disorn ; Schock, Helena ; Johnson, Theron ; Tjønneland, Anne ; Olsen, Anja ; Overvad, Kim ; Clavel-Chapelon, Françoise ; Dossus, Laure ; Baglietto, Laura ; Rinaldi, Sabina ; Chajes, Veronique ; Romieu, Isabelle ; Boeing, Heiner ; Schütze, Madlen ; Trichopoulou, Antonia ; Lagiou, Pagona ; Trichopoulos, Dimitrios ; Palli, Domenico ; Sieri, Sabina ; Tumino, Rosario ; Ricceri, Fulvio ; Mattiello, Amalia ; Buckland, Genevieve ; Ramón Quirós, Jose ; Sánchez, María José ; Amiano, Pilar ; Chirlaque, Maria Dolores ; Barricarte, Aurelio ; Bas Bueno-De-Mesquita, H. ; Van Gils, Carla H. ; Peeters, Petra H. ; Andersson, Anne ; Sund, Malin ; Weiderpass, Elisabete ; Khaw, Kay Tee ; Wareham, Nick ; Key, Timothy J. ; Travis, Ruth C. ; Merritt, Melissa A. ; Gunter, Marc J. ; Riboli, Elio ; Lukanova, Annekatrin. / Premenopausal serum sex hormone levels in relation to breast cancer risk, overall and by hormone receptor status - Results from the EPIC cohort. In: International Journal of Cancer. 2014 ; Vol. 134, No. 8. pp. 1947-1957.
@article{df17d4a93cfc4966a621ab78698d3909,
title = "Premenopausal serum sex hormone levels in relation to breast cancer risk, overall and by hormone receptor status - Results from the EPIC cohort",
abstract = "Results from prospective studies on premenopausal serum hormone levels in relation to breast cancer risk have been inconclusive, especially with regard to tumor subtypes. Using a case-control study nested within the prospective European Prospective Investigation into Cancer and Nutrition (EPIC) cohort (801 breast cancer cases and 1,132 matched control subjects), we analyzed the relationships of prediagnostic serum estradiol, free estradiol, progesterone, testosterone, free testosterone and sex hormone-binding globulin (SHBG) levels with the risk of breast cancer by estrogen and progesterone receptor-positive and -negative breast tumors and by age at diagnoses. Higher prediagnostic serum levels of testosterone and free testosterone were associated with an increased overall risk of breast cancer [ORQ4-Q1 = 1.56 (95{\%} CI 1.15-2.13), ptrend = 0.02 for testosterone and ORQ4-Q1 = 1.33 (95{\%} CI 0.99-1.79), ptrend = 0.04 for free testosterone], but no significant risk association was observed for estradiol, free estradiol, progesterone and SHBG. Tests for heterogeneity between receptor-positive and -negative tumors were not significant. When analysis were stratified by age at tumor diagnosis, the odds ratios observed for estradiol were stronger and borderline significant for breast cancer diagnosed at age less than 50 [ORQ4-Q1 = 1.32 (95{\%} CI 0.87-2.01), ptrend = 0.05] compared to breast cancer diagnosed at age 50 or above [ORQ4-Q1 = 0.94 (95{\%} CI 0.60-1.47), ptrend = 0.34, phet = 0.04]. In conclusion, our data indicate that higher premenopausal circulating testosterone levels are associated with an increased risk of developing breast cancer, but do not show a significant association of estradiol or progesterone with breast cancer risk, overall, by menstrual cycle phase or by tumor receptor status, although a possible risk increase with higher estradiol levels for tumors diagnosed before age 50 was seen. What's new? Sex hormones have often been connected with the development of breast cancer, and estrogens have clear pro-proliferative effects on breast cancer cells. In this large prospective study, the authors underscore a direct association of premenopausal levels of testosterone with subsequent breast cancer risk. By contrast, no direct relationship between premenopausal estrogen and progesterone levels with increased breast cancer risk was observed although a weak association between higher estradiol levels and increased risk for tumors diagnosed before age 50 was noted. The authors point to the possibility that a conversion from androgen to estrogen might take place in the breast that may mechanistically explain the increased risk in breast cancer development when androgens are high.",
keywords = "breast cancer, EPIC, estrogen receptor, prospective cohort, sex hormones",
author = "Rudolf Kaaks and Kaja Tikk and Disorn Sookthai and Helena Schock and Theron Johnson and Anne Tj{\o}nneland and Anja Olsen and Kim Overvad and Fran{\cc}oise Clavel-Chapelon and Laure Dossus and Laura Baglietto and Sabina Rinaldi and Veronique Chajes and Isabelle Romieu and Heiner Boeing and Madlen Sch{\"u}tze and Antonia Trichopoulou and Pagona Lagiou and Dimitrios Trichopoulos and Domenico Palli and Sabina Sieri and Rosario Tumino and Fulvio Ricceri and Amalia Mattiello and Genevieve Buckland and {Ram{\'o}n Quir{\'o}s}, Jose and S{\'a}nchez, {Mar{\'i}a Jos{\'e}} and Pilar Amiano and Chirlaque, {Maria Dolores} and Aurelio Barricarte and {Bas Bueno-De-Mesquita}, H. and {Van Gils}, {Carla H.} and Peeters, {Petra H.} and Anne Andersson and Malin Sund and Elisabete Weiderpass and Khaw, {Kay Tee} and Nick Wareham and Key, {Timothy J.} and Travis, {Ruth C.} and Merritt, {Melissa A.} and Gunter, {Marc J.} and Elio Riboli and Annekatrin Lukanova",
year = "2014",
month = "4",
day = "15",
doi = "10.1002/ijc.28528",
language = "English",
volume = "134",
pages = "1947--1957",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "8",

}

TY - JOUR

T1 - Premenopausal serum sex hormone levels in relation to breast cancer risk, overall and by hormone receptor status - Results from the EPIC cohort

AU - Kaaks, Rudolf

AU - Tikk, Kaja

AU - Sookthai, Disorn

AU - Schock, Helena

AU - Johnson, Theron

AU - Tjønneland, Anne

AU - Olsen, Anja

AU - Overvad, Kim

AU - Clavel-Chapelon, Françoise

AU - Dossus, Laure

AU - Baglietto, Laura

AU - Rinaldi, Sabina

AU - Chajes, Veronique

AU - Romieu, Isabelle

AU - Boeing, Heiner

AU - Schütze, Madlen

AU - Trichopoulou, Antonia

AU - Lagiou, Pagona

AU - Trichopoulos, Dimitrios

AU - Palli, Domenico

AU - Sieri, Sabina

AU - Tumino, Rosario

AU - Ricceri, Fulvio

AU - Mattiello, Amalia

AU - Buckland, Genevieve

AU - Ramón Quirós, Jose

AU - Sánchez, María José

AU - Amiano, Pilar

AU - Chirlaque, Maria Dolores

AU - Barricarte, Aurelio

AU - Bas Bueno-De-Mesquita, H.

AU - Van Gils, Carla H.

AU - Peeters, Petra H.

AU - Andersson, Anne

AU - Sund, Malin

AU - Weiderpass, Elisabete

AU - Khaw, Kay Tee

AU - Wareham, Nick

AU - Key, Timothy J.

AU - Travis, Ruth C.

AU - Merritt, Melissa A.

AU - Gunter, Marc J.

AU - Riboli, Elio

AU - Lukanova, Annekatrin

PY - 2014/4/15

Y1 - 2014/4/15

N2 - Results from prospective studies on premenopausal serum hormone levels in relation to breast cancer risk have been inconclusive, especially with regard to tumor subtypes. Using a case-control study nested within the prospective European Prospective Investigation into Cancer and Nutrition (EPIC) cohort (801 breast cancer cases and 1,132 matched control subjects), we analyzed the relationships of prediagnostic serum estradiol, free estradiol, progesterone, testosterone, free testosterone and sex hormone-binding globulin (SHBG) levels with the risk of breast cancer by estrogen and progesterone receptor-positive and -negative breast tumors and by age at diagnoses. Higher prediagnostic serum levels of testosterone and free testosterone were associated with an increased overall risk of breast cancer [ORQ4-Q1 = 1.56 (95% CI 1.15-2.13), ptrend = 0.02 for testosterone and ORQ4-Q1 = 1.33 (95% CI 0.99-1.79), ptrend = 0.04 for free testosterone], but no significant risk association was observed for estradiol, free estradiol, progesterone and SHBG. Tests for heterogeneity between receptor-positive and -negative tumors were not significant. When analysis were stratified by age at tumor diagnosis, the odds ratios observed for estradiol were stronger and borderline significant for breast cancer diagnosed at age less than 50 [ORQ4-Q1 = 1.32 (95% CI 0.87-2.01), ptrend = 0.05] compared to breast cancer diagnosed at age 50 or above [ORQ4-Q1 = 0.94 (95% CI 0.60-1.47), ptrend = 0.34, phet = 0.04]. In conclusion, our data indicate that higher premenopausal circulating testosterone levels are associated with an increased risk of developing breast cancer, but do not show a significant association of estradiol or progesterone with breast cancer risk, overall, by menstrual cycle phase or by tumor receptor status, although a possible risk increase with higher estradiol levels for tumors diagnosed before age 50 was seen. What's new? Sex hormones have often been connected with the development of breast cancer, and estrogens have clear pro-proliferative effects on breast cancer cells. In this large prospective study, the authors underscore a direct association of premenopausal levels of testosterone with subsequent breast cancer risk. By contrast, no direct relationship between premenopausal estrogen and progesterone levels with increased breast cancer risk was observed although a weak association between higher estradiol levels and increased risk for tumors diagnosed before age 50 was noted. The authors point to the possibility that a conversion from androgen to estrogen might take place in the breast that may mechanistically explain the increased risk in breast cancer development when androgens are high.

AB - Results from prospective studies on premenopausal serum hormone levels in relation to breast cancer risk have been inconclusive, especially with regard to tumor subtypes. Using a case-control study nested within the prospective European Prospective Investigation into Cancer and Nutrition (EPIC) cohort (801 breast cancer cases and 1,132 matched control subjects), we analyzed the relationships of prediagnostic serum estradiol, free estradiol, progesterone, testosterone, free testosterone and sex hormone-binding globulin (SHBG) levels with the risk of breast cancer by estrogen and progesterone receptor-positive and -negative breast tumors and by age at diagnoses. Higher prediagnostic serum levels of testosterone and free testosterone were associated with an increased overall risk of breast cancer [ORQ4-Q1 = 1.56 (95% CI 1.15-2.13), ptrend = 0.02 for testosterone and ORQ4-Q1 = 1.33 (95% CI 0.99-1.79), ptrend = 0.04 for free testosterone], but no significant risk association was observed for estradiol, free estradiol, progesterone and SHBG. Tests for heterogeneity between receptor-positive and -negative tumors were not significant. When analysis were stratified by age at tumor diagnosis, the odds ratios observed for estradiol were stronger and borderline significant for breast cancer diagnosed at age less than 50 [ORQ4-Q1 = 1.32 (95% CI 0.87-2.01), ptrend = 0.05] compared to breast cancer diagnosed at age 50 or above [ORQ4-Q1 = 0.94 (95% CI 0.60-1.47), ptrend = 0.34, phet = 0.04]. In conclusion, our data indicate that higher premenopausal circulating testosterone levels are associated with an increased risk of developing breast cancer, but do not show a significant association of estradiol or progesterone with breast cancer risk, overall, by menstrual cycle phase or by tumor receptor status, although a possible risk increase with higher estradiol levels for tumors diagnosed before age 50 was seen. What's new? Sex hormones have often been connected with the development of breast cancer, and estrogens have clear pro-proliferative effects on breast cancer cells. In this large prospective study, the authors underscore a direct association of premenopausal levels of testosterone with subsequent breast cancer risk. By contrast, no direct relationship between premenopausal estrogen and progesterone levels with increased breast cancer risk was observed although a weak association between higher estradiol levels and increased risk for tumors diagnosed before age 50 was noted. The authors point to the possibility that a conversion from androgen to estrogen might take place in the breast that may mechanistically explain the increased risk in breast cancer development when androgens are high.

KW - breast cancer

KW - EPIC

KW - estrogen receptor

KW - prospective cohort

KW - sex hormones

UR - http://www.scopus.com/inward/record.url?scp=84893719571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893719571&partnerID=8YFLogxK

U2 - 10.1002/ijc.28528

DO - 10.1002/ijc.28528

M3 - Article

C2 - 24155248

AN - SCOPUS:84893719571

VL - 134

SP - 1947

EP - 1957

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 8

ER -